Objective: We sought to analyze the outcomes of revascularization for aortoiliac-femoral occlusive disease by comparing hybrid repair by endovascular revascularization and open common femoral endarterectomy (ER-CFE) with open aortoiliac reconstruction and CFE (OR-CFE).
Results: After exclusions, the cohort comprised 879 patients in the OR-CFE group and 1472 in the ER-CFE group with follow-up of at least 9 months. Patients with ER-CFE were older (68 6 9 years vs 63 6 9 years; P < .001) and were more likely to have diabetes (37% vs 29%; P < .001) or heart failure (13% vs 9%; P < .01). Those receiving OR-CFE were more likely to have received a previous inflow procedure (27% vs 21%; P < .001). A greater number of arterial segments were treated or bypassed for patients undergoing OR-CFE (5.2 6 1.6 vs 2.9 6 1.0; P < .01). ER-CFE was associated with lower 30-day mortality (1.8% vs 3.4%; P ¼ .01), shorter length of stay (median 3 vs 7 days; P < .001), and higher 1-year mortality (8.6% vs 6.3%; P ¼ .04). The two cohorts had equivalent major amputation rate (2.8% vs 2.9%; P ¼ .84). Patients with OR-CFE had greater ABI improvement at long-term follow-up (0.39 6 0.37 vs 0.26 6 0.23; P < .001) and were more likely to achieve improved ambulatory status (82% vs 65%; P < .001).
Conclusions: For patients with aortoiliac-femoral occlusive disease, endovascular repair with concomitant CFE appeared to have improved short-term outcomes and equivalent freedom from major amputation compared with open surgical repair with CFE. Conversely, open repair with CFE was associated with better long-term improvement in ABI and ambulatory status. Open repair should therefore be considered for patients with aortoiliac-femoral occlusive disease and reasonable surgical risk. (J Vasc Surg 2018; 67:199-205.) Aortoiliac-femoral occlusive disease is one of the most challenging manifestations of arterial atherosclerosis in elderly patients, often leading to severe and debilitating clinical presentations. Patients with aortoiliac-femoral occlusive disease continue to represent a challenge in the surgeon's decision-making process owing to the fact that lesions affect multiple segments of the arterial tree, and the patient-specific comorbidities make it more difficult to balance risk and benefits of open vs endovascular treatment.
TransAtlantic Inter-Society Consensus II (TASC II) guidelines, 1 
METHODS
Data set. The Society for Vascular Surgery (SVS) VQI is an evolution of the former Vascular Study Group of New England. Since its institution in 2011, it collects data on 12 major vascular procedures from >370 academic and community hospitals in the United States and Canada as a collaborative network of vascular specialists that aims to improve the quality and safety of vascular care. The VQI collects important clinical data, such as preoperative risk factors, symptom severity, in-depth intraprocedural variables, postprocedure outcomes, and 1-year follow-up data. 4 Patient cohort. We performed a retrospective review of patients enrolled in the SVS VQI database who underwent open or endovascular revascularization of the aortoiliac-femoral system and who additionally underwent concomitant unilateral or bilateral CFE between January 2009 and September 2015. We collected data from the Peripheral Vascular Intervention and Suprainguinal Bypass registries.
Inclusion and exclusion criteria. Patients were included in this study if CFE was performed simultaneously at the time of either open or endovascular aortoiliac revascularization. Patients with aneurysmal disease were excluded, as were those who underwent extra-anatomic bypass or simultaneous revascularization distal to the common femoral artery. Patients with onset of acute ischemia were also excluded from our analysis. Following the VQI policy for quality improvement research, we excluded from our analysis data from centers with <50% 9-month or longer follow-up of surviving patients. The final cohort was representative of the entire population with regard to demographics, preoperative ambulatory status, American Society of Anesthesiologists (ASA) class, and preoperative ankle-brachial index (ABI; Supplementary Table, online only).
Baseline characteristics of the patients. Demographic characteristics included age, sex, ambulatory status before surgery, and preoperative ABI. Preoperative risk factor assessment included diabetes mellitus, coronary artery disease including history of myocardial infarction >6 months before surgery, history of cardiac surgery (coronary artery bypass graft or percutaneous coronary intervention), chronic heart failure, chronic obstructive pulmonary disease, smoking (both current and prior history of smoking), renal insufficiency (defined as serum creatinine concentration of >1.78 mg/dL), current dialysis at the time of surgery, and ASA class. Preoperative assessment also included indication to procedure, previous inflow or outflow vascular procedures, and previous major amputations ipsilateral to the side of treatment. Operative characteristics included the side treated (bilateral or unilateral procedure), the type of procedure, and the number of arteries treated or bypassed during the procedure (counted as number of arteries treated for ER-CFE and the number of arteries treated or bypassed, including donor and recipient artery, for OR-CFE).
Outcomes. Following the VQI policy for quality improvement research, we excluded from any analyses the data from centers that reported 9-month or longer follow-up in <50% of surviving patients as these centers may have biased reported outcomes. Outcomes were reported at the patient level. Primary early outcomes of interest were 30-day mortality and length of stay (LOS). Primary 1-year outcomes included 1-year mortality (verified with both VQI input record and Social Security Death Index), improvement in ABI (calculated as difference between preoperative ABI and ABI at follow-up visit), improvement in ambulatory status, primary patency, need of reinterventions, and major ipsilateral amputations. In addition, we analyzed outcomes in relation to hospital volumes. We divided centers in equal quintiles based on yearly volumes for each of the OR-CFE and ER-CFE groups. We defined high volume as the highest quintile, low-volume as the lowest quintile, and midvolume as the second through fourth quintile.
Statistical analysis. Univariate and bivariate analysis was performed using t-test or Wilcoxon rank sum for continuous variables and two-tailed c 2 for categorical variables. Linear regression analysis of improvement in ABI was performed including independent variables significantly associated with the outcome variable on univariate analysis. Similar analysis was performed on categorical outcome variables using multivariable logistic regression modeling. Operator and hospital volume was incorporated into models by dividing average yearly volumes into quintiles. Operators or centers in the lowest quintile were defined as low volume; those in the highest quintile, high volume; and the second to fourth quintiles, midvolume. A P value of <.05 was considered statistically significant for all the analyses.
As we used fully deidentified data from the SVS VQI database, the study was deemed exempt by the Stanford University Institutional Review Board; likewise, informed consent was not required. Data analysis was performed using Stata 14.1 (StataCorp LP, College Station, Tex).
RESULTS
During the study period, 1234 patients received OR-CFE (2054 legs) and 2246 patients underwent ER-CFE (2935 legs), for a total of 3480 patients treated in 165 centers across the United States and Ontario. Of the cohort, 1139 (32.6%) were excluded from 88 (53%) centers that reported <50% 9-month or longer follow-up in surviving patients. After exclusions, the final cohort comprised 879 patients receiving OR-CFE and 1472 receiving ER-CFE. By comparison, patients undergoing OR-CFE were younger (63 6 9 years vs 68 6 9 years; P < .001) and were less likely to have diabetes (P < .001), coronary artery disease (P < .001), congestive heart failure (P < .001), or chronic kidney disease (P ¼ .004) or to be under dialysis treatment (P < .001; Table I ). The majority of the patients in both groups received treatment for claudication, but although claudication and rest pain were more common in the OR-CFE group, tissue loss and acute ischemia were more common in the ER-CFE cohort (P < .001). Those receiving OR-CFE were more likely to have received a previous inflow open procedure (P < .001) Preoperative ABIs were similar in both groups, as was ASA class.
Bilateral revascularization was more common for those who underwent OR-CFE (84% vs 30%; P < .001), and for this group, the mean number of arteries treated or bypassed was significantly higher compared with ER-CFE patients (5.2 6 1.6 vs 2.9 6 1.0; P < .01; Table II ).
The majority of the OR-CFE group received aortobifemoral bypass (81%), whereas the majority of the ER-CFE group received stents (79% bare-metal stents, 17% covered stents).
Outcomes after revascularization are summarized in Table III . The 30-day morality was higher for OR-CFE (3.4% vs 1.8%; P ¼ .01), as was median LOS (7 days [interquartile range, 5-11] vs 3 days [interquartile range, 2-6]; P < .001) and discharge to other than home (24.1% vs 20.7%; P ¼ .037). Long-term follow-up of at least 9 months was available in 1343 (57%) of cases. The two treatment groups had equivalent 1-year primary patency (OR-CFE, 81%; ER-CFE, 79%) and major amputation rates (2.9% vs 2.8%). Unadjusted 1-year mortality was higher after ER-CFE (8.6% vs 6.3%; P ¼ .01).
ABIs were available for 49% of those with clinical follow-up. At follow-up, patients with OR-CFE had greater improvement in ABI (0.39 6 0.37 vs 0.26 6 0.23; P < .001) and were more likely to have achieved improved ambulatory status (82% vs 65%; P < .001) compared with those receiving ER-CFE (Table III) . As such, only 18% of OR-CFE patients failed to improve ambulatory status compared with 33% of ER-CFE patients. Of those with improved ambulatory status, patients who were ambulatory without assistance before intervention achieved the greatest gains with OR-CFE compared with ER-CFE (84% improved vs 68% improved; P < .001; Table IV) .
After adjustment for baseline preoperative characteristics significantly associated with the outcome variable on univariate analysis (age, gender, diabetes, coronary artery disease, previous open inflow procedures, previous endovascular outflow procedures, indication, smoking, chronic obstructive pulmonary disease, renal failure, and preoperative ambulatory status), improvement in ABI remained significantly higher in the OR-CFE group (0.39 6 0.03 vs 0.27 6 0.02; P < .001; Table V, A). In addition, multivariate logistic regression showed an increase in the likelihood of improvement of the ambulatory In stratifying by hospital procedural volume, lowvolume OR-CFE centers reported an average of <5 reconstructions during the study period, and highvolume centers reported an average of 53 cases. Lowvolume ER-CFE centers reported an average of 7 cases, and high-volume ER-CFE centers reported an average of 133 cases. Hospital procedural volume appeared to have an impact on short-term and long-term outcomes. Early mortality was similar, with differences in LOS and discharge to home (Table VI) . At 1 year, improved patency was observed after OR-CFE (96% in high-volume centers vs 77% in low-volume centers; P ¼ .005) and ER-CFE (91% in high-volume centers vs 78% in low-volume centers; P ¼ .03). Procedural volume had no impact on improved ambulatory status or improvement in ABI.
DISCUSSION
The majority of the procedures performed for aortoiliacfemoral occlusive disease reported in our series were ER-CFE. This observation reflects the treatment paradigm shift of the last decade of increased use of endovascular and hybrid techniques as the first-line strategy of treatment, even for extensive lesions traditionally treated with open repair. [5] [6] [7] To our knowledge, this study is the largest population-based study to date comparing surgical and endovascular or hybrid treatment of aortoiliac-femoral occlusive disease with access to periprocedural and follow-up clinical data and the first to reveal a higher improvement in ABI and ambulatory functional status in patients who underwent open revascularization compared with patients who underwent a hybrid approach. Our study adds to the findings of previous single-center studies that have reported a 75% to 90% primary patency and 95% to 98% secondary patency at 3 to 5 years after hybrid repair. 3 9 In this series, for which 85% were treated for critical limb ischemia, the increase of the ABI and improvement of the Rutherford category were equivalent for both treatment groups, and there were no statistically significant differences in the primary, primary assisted, and secondary patency rates at 36 months. Our findings support the importance of measuring and reporting long-term functional outcomes after arterial revascularization. 10, 11 As expected, in our series, patients who underwent hybrid repair were older and with more comorbidities compared with patients who had been offered an open surgical approach. Although traditionally reported short-term outcomes including LOS and early mortality were better for those receiving ER-CFE, 1-year mortality and patency rates were equivalent. Conversely, improvement in ABIs and ambulatory status was better for those receiving open repair. Understanding the differences in functional outcomes will add meaning to the decision-making process when a choice is available in treatment options and may be critically important for alignment between the physician and patient based on benefits, risks, and goals of care.
This study has some notable limitations. Most important, TASC classification was not reported for those receiving open repair. We could therefore not compare the severity of treated disease between groups.
Although those receiving open surgery had more vessels treated or bypassed, it is possible that they had only limited aortoiliac disease. However, there was no difference between the groups with regard to symptoms of critical limb ischemia (52% for OR-CFE vs 53% for ER-CFE; P ¼ .7), previous outflow procedures (14% for OR-CFE vs 15% for ER-CFE; P ¼ .4), or preprocedural ABIs (0.56 6 0.28 for OR-CFE vs 0.58 6 0.38 for ER-CFE; P ¼ .11). As those with subsequent outflow procedures were not included in the study, we believe the overall disease burden was likely similar and does not detract from our findings of improved ambulatory status and improved ABIs.
As with any retrospective analysis, unmeasured treatment bias may be present; however, despite the nonrandomized nature of this study, the two groups were well matched for baseline characteristics, risk factors, and clinical variables. Certain elements were not available, including follow-up past 1 year and Rutherford classification. For this reason, we could analyze ambulatory functional status but with no specific information on claudication distances. Therefore, for patients who were ambulatory without assistance preoperatively, we considered them to have an improvement in their ambulatory status if they maintained their ambulatory status with an improved ABI at follow-up visit of at least 0.15 compared with preoperative assessment. In addition, no quality of life data were available, preventing our ability to interpret improved functional status to patient-perceived outcomes. 12 
CONCLUSIONS

